Is Elevation of Alkaline Phosphatase a Predictive Factor of Response to Alectinib in NSCLC?

Is Elevation of Alkaline Phosphatase a Predictive Factor of Response to Alectinib in NSCLC?

In the following report, we describe a case of alkaline phosphatase (ALP) elevation occurring during treatment with alectinib (Alecensa™), which was administered for anaplastic lymphoma kinase (ALK) mutated metastatic non-small cell lung cancer (mNSCLC). A 51 year-old female with widespread metastat...

Full description

Bibliographic Details
Main Authors:	Walid Shalata, Alexander Yakobson, Rachel Steckbeck, Ashraf Abu Jama, Omar Abu Saleh, Abed Agbarya
Format:	Article
Language:	English
Published:	MDPI AG 2021-12-01
Series:	Current Oncology
Subjects:	lung adenocarcinoma ALK mutation Alecensa<sup>®</sup> (Alectinib) alkaline phosphatase (ALP) toxicity
Online Access:	https://www.mdpi.com/1718-7729/29/1/16

Similar Items

Efficacy and Safety of Dose-Escalated Alectinib in Patients With Metastatic ALK-Positive NSCLC and Central Nervous System Relapse on Standard-Dose Alectinib
by: Justin M. Cheung, MD, et al.
Published: (2024-03-01)

Alectinib and lorlatinib function by modulating EMT-related proteins and MMPs in NSCLC metastasis
by: Xu Feng, et al.
Published: (2021-06-01)

Clinical case of prolonged use of alectinib in the treatment of ALK-positive NSCLC
by: S. G. Bagrova, et al.
Published: (2019-12-01)

Sensitive Fluorescence Assay for the Detection of Alkaline Phosphatase Based on a Cu<sup>2+</sup>-Thiamine System
by: Han Zhao, et al.
Published: (2021-01-01)

Alkaline phosphatase interference in immuno-enzymatic assays
by: Oğuz Osman, et al.
Published: (2022-01-01)

A novel SLC8A1-ALK fusion in lung adenocarcinoma confers sensitivity to alectinib: A case report
by: Deng Ling, et al.
Published: (2022-08-01)

Comparative Efficacy and Safety of Lorlatinib and Alectinib for ALK-Rearrangement Positive Advanced Non-Small Cell Lung Cancer in Asian and Non-Asian Patients: A Systematic Review and Network Meta-Analysis
by: Koichi Ando, et al.
Published: (2021-07-01)

Early Development of Ubiquitous Acanthocytosis and Extravascular Hemolysis in Lung Cancer Patients Receiving Alectinib
by: Julia Kunz, et al.
Published: (2022-05-01)

Concomitant double-fusion of PLEKHA7-ALK and INPP5D-ALK reveals favorable alectinib sensitivity in lung adenocarcinoma: a case report and literature review
by: Pei Li, et al.
Published: (2024-02-01)

Spontaneous Bilateral Chylothorax Development During Alectinib Therapy for ALK-Rearranged NSCLC—A Case Report
by: Sunanjay Bajaj, MD, et al.
Published: (2023-12-01)

Pathological complete response to long-course neoadjuvant alectinib in lung adenocarcinoma with EML4-ALK rearrangement: report of two cases and systematic review of case reports
by: Liang Shi, et al.
Published: (2023-06-01)

Alkaline Phosphatase (ALP) in Non-Cow Milk and Dairy Products: A Review of Current Evidence and Future Trends
by: Eleni Malissiova, et al.
Published: (2022-11-01)

Remarkable response to alectinib for metastatic papillary thyroid cancer with STRN-ALK fusion: A case report
by: Lucheng Zhu, et al.
Published: (2022-11-01)

Sustained Improvement in the Management of Patients with Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocation: Where Are We Running?
by: Gianluca Spitaleri, et al.
Published: (2023-05-01)

Case Report: ALK rearranged locally advanced lung adenocarcinoma showing inconsistent radiographic findings and pathological responses during neoadjuvant alectinib therapy
by: Peijun Cao, et al.
Published: (2023-08-01)

Zinc Deficiency Promotes Calcification in Vascular Smooth Muscle Cells Independent of Alkaline Phosphatase Action and Partly Impacted by Pit1 Upregulation
by: Ethel H. Alcantara, et al.
Published: (2024-01-01)

Perimyocarditis Associated with Immune Checkpoint Inhibitors: A Case Report and Review of the Literature
by: Walid Shalata, et al.
Published: (2024-01-01)

Case report: Drug-drug interaction between alectinib and apixaban in NSCLC
by: J.L. Gulikers, et al.
Published: (2022-09-01)

Mammalian alkaline phosphatases : from biology to applications in medicine and biotechnology /
by: 249818 Millan, Jose Luis
Published: (2006)

Case report: Dramatic response to alectinib in a lung adenosquamous carcinoma patient harbouring a novel CPE-ALK fusion
by: Yanyan Qin, et al.
Published: (2022-12-01)

The Effect of Vitamin D Level on Parathyroid Hormone and Alkaline Phosphatase
by: Hussein Abdullah Rajab
Published: (2022-11-01)

A Combination of Alectinib and DNA-Demethylating Agents Synergistically Inhibits Anaplastic-Lymphoma-Kinase-Positive Anaplastic Large-Cell Lymphoma Cell Proliferation
by: Kazunori Kawasoe, et al.
Published: (2023-10-01)

Evaluation of Efficacy of ALK Inhibitors According to Body Mass Index in ALK Rearranged NSCLC Patients—A Retrospective Observational Study
by: Marco Siringo, et al.
Published: (2023-06-01)

Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced ALK-Positive NSCLC
by: Dong-Wan Kim, MD, PhD, et al.
Published: (2022-08-01)

Novel PPFIA1-ALK, ALK-C2orf91(intergenic) double-fusion responded well to alectinib in an advanced lung adenocarcinoma patient: a case report
by: Lingxin Yan, et al.
Published: (2023-08-01)

Changing ALK-TKI-Resistance Mechanisms in Rebiopsies of <i>ALK</i>-Rearranged NSCLC: <i>ALK</i>- and <i>BRAF</i>-Mutations Followed by Epithelial-Mesenchymal Transition
by: Edyta M. Urbanska, et al.
Published: (2020-04-01)

FINDING HYPOPHOSPHASIA. LOW LEVEL OF ALKALINE PHOSPHATASE PATIENTS SCREENING
by: A. V. Vitebskaya, et al.
Published: (2017-12-01)

Multiple Myeloma and Alkaline Phosphatase
by: İrfan Yavaşoğlu, et al.
Published: (2015-05-01)

Efficacy of Crizotinib, Ceritinib, and Alectinib in ALK-Positive Non-Small Cell Lung Cancer Treatment: A Meta-Analysis of Clinical Trials
by: Tung Hoang, et al.
Published: (2020-02-01)

Phase II Trial of the Combination of Alectinib with Bevacizumab in Alectinib Refractory <i>ALK</i>-Positive Nonsquamous Non-Small-Cell Lung Cancer (NLCTG1501)
by: Satoshi Watanabe, et al.
Published: (2022-12-01)

Exceptional response to alectinib for duodenal carcinoma with ALK fusion: A case report and literature review
by: Yuri Isaka, et al.
Published: (2023-01-01)

ALESIA 5-Year Update: Alectinib at 600 mg Twice Daily Gives Lorlatinib a Run for Its Money in Asia
by: Lee AT, et al.
Published: (2023-07-01)

Alectinib-Induced Severe Hemolytic Anemia in a Patient with ALK-Positive Non-Small Cell Lung Cancer: A Case Report
by: Misawa K, et al.
Published: (2023-01-01)

The effects of chromium and cadmium on the activity of alkaline phosphatase lsoenzmes in rats
by: S.A.A Moshtaghi, et al.
Published: (1995-09-01)

Reappraisal of the Role of Alkaline Phosphatase in Hepatocellular Carcinoma
by: Chun-Wei Huang, et al.
Published: (2022-03-01)

A Systematic Review of Companion Diagnostic Tests by Immunohistochemistry for the Screening of Alectinib-Treated Patients in ALK-Positive Non-Small Cell Lung Cancer
by: Sulim Kang, et al.
Published: (2022-05-01)

Hemolytic anemia caused by alectinib, an Anaplastic Lymphoma Kinase (ALK) inhibitor: A case report
by: Robina Aerts, et al.
Published: (2022-09-01)

Normal distribution of alkaline phosphatase levels during pregnancy
by: Nissim Arbib, et al.
Published: (2021-12-01)

Successful Alectinib Treatment for Carcinoma of Unknown Primary with <i>EML4-ALK</i> Fusion Gene: A Case Report
by: Keiji Sugiyama, et al.
Published: (2021-05-01)

Acquired L1196M ALK mutation in anaplastic lymphoma kinase‐positive anaplastic large cell lymphoma during alectinib administration
by: Kazuhiro Noguchi, et al.
Published: (2023-02-01)